Eli Lilly

Eli Lilly’s Dual-Pronged Strategy to Fortify Its Weight-Loss Market Dominance

kashif hafeez - March 12, 2026

Eli Lilly’s Strategic Horizon: Pipeline Milestones and Market Expansion

March 5, 2026

Eli Lilly Positions Oral Obesity Drug for Potential 2026 Launch

kashif hafeez - March 3, 2026

Eli Lilly’s Robust Pipeline Fuels Long-Term Growth Outlook

Brett Shapiro - February 22, 2026

Eli Lilly Bolsters Growth Trajectory with Triple Pipeline Advancements

kashif hafeez - February 20, 2026

Eli Lilly Bolsters Pipeline with Strategic Deals Following Strong Earnings

Brett Shapiro - February 11, 2026

Eli Lilly Launches Strategic Expansion with Multi-Billion Dollar Moves

February 10, 2026

Eli Lilly’s Market Leadership Strengthens on Robust Outlook

angelina - February 6, 2026

Eli Lilly Accelerates Growth Strategy Through Strategic Collaborations

kashif hafeez - January 30, 2026

Eli Lilly’s Strategic Pipeline and Partnerships Drive Investor Confidence

January 20, 2026

Eli Lilly Faces Regulatory Setback for Key Obesity Drug Candidate

January 18, 2026

Eli Lilly Faces Regulatory Delay for Key Obesity Drug

angelina - January 17, 2026

Eli Lilly Faces New Challenge in Weight-Loss Drug Race

kashif hafeez - December 24, 2025

Eli Lilly Positions Oral Weight-Loss Drug as Formidable Rival to Novo Nordisk

Brett Shapiro - December 19, 2025

Eli Lilly Strengthens Obesity Portfolio with Promising Trial and Strategic Alliance

December 17, 2025

12 3 Page 1 of 3